Drug Topics April 16, 2024
A study from the Karolinska Institutet found that 76 out of 145410 patients treated with a GLP-1 developed thyroid cancer during nearly 4 years of follow-up.
Glucagon-like peptide 1 (GLP-1) receptor agonist use does not significantly increase the risk of thyroid cancer, according to new research published in BMJ.1 However, the authors noted that the study results cannot exclude a small increase in risk.
GLP-1s, which are approved to treat type 2 diabetes and weight loss, have experienced a rapid increase in use recently. For example, semaglutide (Ozempic) users increased from 569 in 2019 to 22891 in 2022.2 Although previous research has found that GLP-1s increased rates of thyroid C cell tumors in rodents, whether these findings are relevant to...
Today's Sponsors
Today's Sponsor